Effects of zero-balanced ultrafiltration on procalcitonin and respiratory function after cardiopulmonary bypass.
The abnormal conditions to which blood is subjected during cardiopulmonary bypass (CPB) trigger an activation of the inflammatory response and cause pulmonary dysfunction. It has been suggested that high-volume, zero-balanced ultrafiltration (ZBUF) facilitates clearance of inflammatory mediators and improves post-operative pulmonary function. Procalcitonin, a newly discovered inflammatory mediator, has been found to be increased after CPB and has been proven to be an appropriate parameter for predicting pulmonary dysfunction secondary to CPB. The aim of this study was to investigate the effects of zero-balanced ultrafiltration (ZBUF) on procalcitonin (PCT) and respiratory function of infants with Tetralogy of Fallot (TOF) after CPB. Twenty infants with TOF undergoing open-heart total surgical correction were randomly assigned to two groups. The trial group was given ZBUF (50 ml/kg) and conventional ultrafiltration (CUF), while the control group was given CUF only. Plasma PCT and pulmonary function were monitored and compared between the two groups before the operation (T1), before rewarming (T2), at the end of the operation (T3), and at 12 h, 24 h and 48 h after the operation (T4-T6). PCT was decreased in the trial group between 12 h and 48 h post-operatively, but the differences did not reach statistical significance. The trial group's pulmonary compliance was higher at 12 h post-operatively (p < 0.05). Oxygenation index was increased in the trial group at the end of the operation and 12 h post-operatively (p > 0.05). Intubation time was shorter in the trial group (P < 0.01). A positive correlation was found between peak PCT concentration and intubation time. ZBUF appeared to improve ventilation and shorten intubation time. The improved respiratory function may be due to the lower plasma PCT.
Song
L O U
LO
Department of Congenital Defect, Cardiovascular Institute and Fu Wai Hospital, CAMS & PUMC, Beijing, PR China.
Yinglong
L I U
LI
Jinping
L I U
LI
D015415:Biomarkers / Q000097:blood; D002116:Calcitonin / Q000097:blood*; D015740:Calcitonin Gene-Related Peptide; D002315:Cardiopulmonary Bypass / Q000379:methods*; D006801:Humans; D007223:Infant; D011183:Postoperative Complications / Q000276:immunology / Q000517:prevention & control*; D011237:Predictive Value of Tests; D011498:Protein Precursors / Q000097:blood*; D012129:Respiratory Function Tests; D012131:Respiratory Insufficiency / Q000276:immunology / Q000517:prevention & control*; D013771:Tetralogy of Fallot / Q000601:surgery; D016896:Treatment Outcome; D014462:Ultrafiltration / Q000379:methods*
D015415:Biomarkers; C000606589:CALCA protein, human; D011498:Protein Precursors; D002116:Calcitonin; D015740:Calcitonin Gene-Related Peptide